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Alternative translationMyc promoter-binding protein-1 (MBP-1) is a shorter protein variant of the glycolytic enzyme
alpha-enolase. Although several lines of evidence indicate that MBP-1 acts as a tumor suppressor,
the cellular mechanisms and signaling pathways underlying MBP-1 expression still remain largely
elusive. To dissect these pathways, we used the SkBr3 breast cancer cell line and non-tumorigenic
HEK293T cells ectopically overexpressing alpha-enolase/MBP-1. Here, we demonstrate that induced
cell stresses promote MBP-1 expression through the AKT/PERK/eIF2a signaling axis. Our results con-
tribute to shedding light on the molecular mechanisms underlying MBP-1 expression in
non-tumorigenic and cancer cells.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Many eukaryotic genes generate protein isoforms and variants
with slightly different/overlapping functions or truncated proteins
that have altered cellular localization and, consequently, alterna-
tive functions. The human ENO1 gene encodes the glycolitic
enzyme alpha-enolase, which normally resides in the cytoplasm
where it contributes to glycolysis, and a shorter protein variant,
Myc promoter-binding protein-1 (MBP-1), which exerts its func-
tion in the nucleus. MBP-1 acts as a transcriptional repressor,and three direct gene targets, c-Myc, COX2 and ERBB2, have been
identiﬁed so far [1–4]. Several reports indicate that MBP-1 acts
as a putative oncosuppressor, negatively regulating cell prolifera-
tion or promoting cancer cell apoptosis when overexpressed
in vitro [5,6]. Moreover, a role for MBP-1 in regulating tumor inva-
sion and metastasis has been proposed for follicular thyroid carci-
noma and gastric cancer, using in vitro and mouse xenograft
models, respectively [7,3].
According to the well-known Warburg effect, cancer cells
highly express almost all glycolytic enzymes, including
alpha-enolase, a phenomenon which in toto confers a growth
advantage, both in hypoxic and normal oxygen conditions, to the
transformed cells [8]; in contrast, and consistent with its negative
regulatory role on cell growth, the endogenous level of MBP-1 is
very low compared to that of alpha-enolase, both in tumor and
non-tumorigenic cell lines.
Miller’s group reported that glucose concentration and hypoxia
modulate MBP-1 expression in the MCF-7 breast cancer cell line
[9,10], and it has been hypothesized that MBP-1 is also
post-translationally regulated in a proteasome-dependent manner
[11]. More recently, MBP-1 has been identiﬁed in Arabidopsis thali-
ana [12,13], and it was conﬁrmed that the blockade of the
ubiquitin-dependent degradation pathways contributes to elevat-
ing the stability of MBP-1 [12]. At present, no other studies
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expression are available.
In breast cancer, we have shown that in almost all cases MBP-1
is easily and consistently detectable in the normal tissue surround-
ing the tumor, while in primary invasive ductal carcinoma (IDC) its
expression varies and is correlated to patient outcome; ultimately,
MBP-1 may be considered a predictor of good disease-free survival
in this type of tumor [14].
The identiﬁcation of novel biomarkers may improve the diagno-
sis, staging and prognostication of tumors and, in the case of breast
cancer patients, due to the common resistance to systemic therapy,
the demand for novel/personalized therapies is continuously
increasing. To this end, we aimed at investigating the only
partially-explored molecular mechanisms underlying MBP-1
expression.
Our own and other previous data support the existence of a sin-
gle ENO1 gene transcript from which both alpha-enolase and
MBP-1 arise through the use of alternative translation initiation
sites [1,2]; one report indicates that a shorter variant transcript,
originating from intron III of the gene, may contribute to MBP-1
expression in a variety of normal tissues and cancer cells [11]. In
the present study, we provide further evidence that MBP-1 arises
through the alternative translation of the transcript encoding
alpha-enolase; furthermore, using a breast cancer cell line and a
cellular model overexpressing alpha-enolase, we identiﬁed for
the ﬁrst time and partially dissected the stress signaling pathways
promoting MBP-1 expression.
2. Material and methods
2.1. Reagents
2-Deoxy-D-glucose and everolimus were purchased from
Sigma–Aldrich; thapsigargin and salubrinal were from Santa Cruz
Biotechnology; NVP-BEZ235 and SC66 were from Cayman
Chemicals; LY 294002 was from Cell Signaling Technologies.
2.2. Cell culture
SkBr3 and MCF-7 cell lines were purchased from American Type
Culture Collection (ATCC, Rockville, MD, USA), and Human
Embryonic Kidney 293T (HEK293T) cells were kindly provided by
Dr. Sandra Pellegrini (Institut Pasteur, Paris, France). Cells were
cultured in DMEM medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 4 mM glutamine and
100 lg/ml penicillin/streptomycin (Sigma–Aldrich). For HEK293T
cells, culture medium was supplemented with 1 mM sodium pyru-
vate (Sigma–Aldrich).
For treatment with inhibitors, SkBr3 or MCF-7 (7  105) and
HEK293T (2  105) cells were cultured in DMEM low-glucose
(1 g/l) (Sigma–Aldrich) plus 10% dialyzed FBS (Gibco, Life
Technologies) on 6-well plates. The next day, cells were incubated
in the same medium supplemented with the indicated amount of
inhibitors; all treatments lasted 24 h.
2.3. Plasmid construction and stable transfection
The full-length Flag-Eno coding sequence was obtained by PCR
with appropriate oligonucleotides, using the pFlag-Eno vector as
template [15], and cloned into the pcDNA4/V5-His expression vec-
tor (Life Technologies); the resulting construct, pFlag-Eno-V5, was
sequenced to verify the open reading frame. Stably transfected
HEK293T cells expressing a multiple-epitope-tagged
alpha-enolase were obtained by the calcium phosphate method,according to standard procedures, and subsequent selection with
200 lg/ml Zeocin (Life Technologies).
2.4. Cell extracts and immunoblotting
Total protein extracts were prepared as previously described
[15]. Total proteins (20–30 lg) were separated on 9% polyacry-
lamide gels and then transferred onto nitrocellulose membrane.
For analyses in Fig. 3, primary antibodies were revealed with
horseradish peroxidase-linked secondary antibodies (GE
Healthcare Life Sciences) and an ECL detection system (Thermo
Scientiﬁc Pierce), as previously described [15]; for all the others
blots the Odyssey infrared imaging system (LI-COR Biosciences)
was used according to the manufacturer’s instructions. Primary
antibodies were: mouse Eno 276/3 and Eno 19/8 against
alpha-enolase [14]; mouse anti-V5 (Life Technologies); rabbit
anti-c-Myc, goat anti-PERK (Santa Cruz Biotechnology); rabbit
anti-phospho-Akt, mouse anti-Akt, rabbit anti-phospho-PERK, rab-
bit anti-phospho-eIF2a, mouse anti-eIF2a (Cell Signaling
Technologies); rabbit anti-ErbB2 (Proteintech), rabbit anti-Flag,
rabbit anti-GRP78/BiP and mouse anti-b-actin (Sigma–Aldrich).
Secondary antibodies were either conjugated to IRDye 800CW
(LI-COR) or Alexa Fluor 680 (Life Technologies).
2.5. Cell viability assay
Cells (5–10  103) were cultured on 96-well plates in
low-glucose medium for 24 h, then in fresh medium containing
different inhibitor doses. MTS assays were performed using the
CellTiter Aqueous OneSolution kit (Promega) according to the
manufacturer’s instructions. Cell viability was expressed as a per-
centage of the absorbance measured in the control cells. Results
from three independent experiments, each performed in triplicate,
were expressed as mean ± SD.
2.6. Small interfering RNA (siRNA) transfection
SkBr3 and HEK293T (6  104 and 2  104, respectively) cells
were cultured in 12-well plates in low-glucose medium. After
24 h, the cells were transfected with pre-validated human PERK
siRNA or control siRNA (Qiagen) at a ﬁnal concentration of 5 nM,
using HiPerFect siRNA transfection reagent according to the man-
ufacturer’s instructions (Qiagen). Cells were harvested and pro-
cessed for immunoblotting 48 h after transfection.
3. Results and discussion
3.1. Glycolysis inhibitor 2-deoxyglucose and the ER stress-inducing
drug thapsigargin promote the expression of MBP-1 in SkBr3 breast
cancer cells
MBP-1 expression has been correlated to the glucose concentra-
tion in the culture medium; speciﬁcally, a low glucose concentra-
tion induces an increase of MBP-1 expression and a decrease of
proliferation in MCF-7 human breast cancer cells [9]. This observa-
tion prompted us to investigate whether the glycolysis inhibitor
2-deoxyglucose (2-DG) may affect MBP-1 expression. The glucose
analog 2-DG mimics glucose deprivation by suppressing the ﬁrst
step of glycolysis and may also induce endoplasmic reticulum
(ER) stress and trigger the unfolded protein response (UPR) [16].
To investigate 2-DG effects on MBP-1 expression, we ﬁrst treated
a breast cancer cell line, SkBr3, with increasing concentrations of
inhibitor in culture conditions close to the ones routinely used,
i.e., simply lowering the glucose concentration in the medium
(see Section 2). As previously reported, endogenous MBP-1
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ERBB2 gene, a recently recognized downstream target of MPB-1;
however, these cells have been shown to retain a physiological
response to MBP-1 overexpression [4]. The time of treatment and
the optimal concentration of 2-DG were determined preliminarily
by a small-scale experiment. MBP-1 protein expression was deter-
mined by immunoblotting and densitometric analysis data were
normalized to b-actin levels. The 2-DG treatment upregulated
MBP-1 in a dose-dependent manner, and the highest level of
MBP-1 expression was observed after treatment with 5–15 mM
2-DG for 24 h, while no signiﬁcant effect on alpha-enolase expres-
sion was detected (Fig. 1A and B).
In order to investigate whether ER stress is involved in MBP-1
expression, SkBr3 breast cancer cells were treated either with
increasing concentrations of 2-DG or thapsigargin (TG). TG is a
highly speciﬁc inhibitor of the sarcoplasmic reticulum and endo-
plasmic reticulum Ca2+-ATPase pump, which causes the elevation
of intracellular calcium, ER stress and ultimately apoptosis if stress
is not resolved through the UPR [17]. We observed a
dose-dependent upregulation of MBP-1 expression following both
2-DG and TG treatments; consistent with the increased expression
of MBP-1, its downstream targets ErbB2 and c-Myc proteins were
downregulated (Fig. 1C). To correlate MBP-1 expression to known
2-DG or TG effects on cellular growth, SkBr3 cells viability was
measured by MTS assay. Cell growth decreased by 60–80% when
cells were treated with 5–15 mM 2-DG for 24 h, while treatment
with TG induced an overall 40% reduction in cell viability
(Fig. 2A and B).
It is known that AKT kinase plays a role in the control of cell
proliferation and cell viability and is involved in the regulation of
energy metabolism. Usually glucose deprivation results in the acti-
vation of AMPK and consequent inhibition of AKT phosphorylation;
however, the activation of AKT kinase following 2-DG treatment
has also been reported [18]. Therefore, we decided to investigate
the relative AKT phosphorylation under our experimental condi-
tions. As expected from the cell viability results, we did not observe
an activation of AKT in 2-DG-treated SkBr3 cells, phosphorylation
of S473 was reduced with respect to control cultures and, overall,
the immunoblotting analysis showed an inverse association
between AKT activity and MBP-1 expression (Fig. 1C, 2-DG). Cells
treated with TG showed an even more signiﬁcant reduction in
phospho-AKT compared to the untreated control (Fig. 1C, TG).
To restore ER homeostasis, the UPR activates a number of pro-
tective mechanisms, including the transient attenuation of protein
translation, the activation of selected gene expression, and the
induction of molecular chaperones and folding enzymes. Among
the actors of the UPR, PERK kinase, eIF2a, ATF4 and the ER chaper-
one glucose-regulated protein 78 (GRP78) are the downstream
effectors of the event cascade which characterizes the response.
Namely, as a response to stress, protein synthesis is mainly
repressed through the blocking of cap-dependent mRNA transla-
tion, exerted by controlling the activity of the translation initiation
factor eIF2a. Under stress conditions, the phosphorylation of eIF2a
by PERK kinase inhibits the correct positioning of the ribosome on
the mRNA start codon; consequently, cap-independent translation
is activated to maintain the required levels of selected proteins
(e.g., ATF4) and, ultimately, to resolve the stress or to induce apop-
tosis. In accordance with these data and conﬁrming the effective-
ness of the treatments, in SkBr3 cells treated with 2-DG or TG we
found upregulated levels of active phospho-PERK (pT980) and
phospho-eIF2a, as well as an increase of ATF4 and GRP78 expres-
sion compared to the untreated control (Fig. 1C). The upregulation
of UPR was dose-dependent and was associated with the induction
of MBP-1 expression, suggesting a correlation between the two
events.3.2. The inhibition of PI3K-AKT signaling upregulates the downstream
PERK/eIF2a pathway and MBP-1 expression
Since MBP-1 is generated by the alternative translation of ENO1
mRNA, the results of 2-DG and TG treatments on SkBr3 cells
strongly suggested that the observed upregulation of MBP-1
expression under ER stress conditions might be regulated by a
cap-independent mechanism switched on following eIF2a
inactivation.
Recently, a link between AKT kinase activity and the phospho-
rylation/inactivation of eIF2a has been found. In physiological
conditions, AKT-mediated phosphorylation of PERK kinase in
T799 maintains low activity; PERK, in this inactive form, does
not phosphorylate and consequently inactivate eIF2a, which in
the unphosphorylated form exerts its routine role in translation
initiation [19]. The treatment of cells with pharmacological inhi-
bitors of PI3K-AKT mimics ER stress induction, resulting in the
downregulation of phospho-AKT, the upregulation of active
PERK kinase (autophosphorylation in T980) and inactive phospho-
eIF2a [19].
To experimentally support the hypothesis of a correlation
between the active/inactive state of AKT, the PERK-mediated phos-
phorylation of eIF2a, and MBP-1 expression, SkBr3 breast cancer
cells were ﬁrst treated with the AKT inhibitor, NVP-BEZ235
(BEZ). This molecule is a dual inhibitor that blocks the activity of
both PI3K and mTOR signaling, competing for binding with ATP
[20]. As expected, the treatment with this inhibitor induced a
decrease of phospho-AKT, while phospho-PERK, phospho-eIF2a,
ATF4 and MBP-1 expression were upregulated (Fig. 1D). As a con-
trol, we evaluated the effects on cell growth; in our experimental
conditions, BEZ treatment decreased cell viability of SkBr3 cells
by 35–40% (Fig. 2C). To further investigate whether the
PERK-mediated translation control downstream of AKT is involved
in the upregulation of MBP-1 expression, we used two inhibitors of
the PI3K/AKT/mTOR pathway, LY294002 (LY) and everolimus
(EVE). LY speciﬁcally inhibits the upstream PI3K, and EVE blocks
the downstream mTOR complex. Consistent with these selective
action mechanisms, LY treatment induced a signiﬁcant decrease
of phospho-AKT in SkBr3 cells, while treatment with EVE did not
have such an effect (Fig. 1D). As a control of EVE treatment, we
monitored the decrease of phospho-p70S6K, which is a down-
stream effector of AKT/mTOR (not shown). In conclusion, both
treatments with LY and BEZ resulted in an increased phosphoryla-
tion/activation of PERK and phosphorylation/inactivation of eIF2a,
and a concomitant upregulation of MBP-1 expression.
These results were in agreement with both the previously
reported data regarding the control exerted by AKT-PERK signaling
on eIF2a activity [19] and our hypothesis of a downstream effect
on MBP-1 translation. To further conﬁrm the putative association
of the AKT/PERK/eIF2a signaling pathway with MBP-1 expression,
we used a novel AKT inhibitor, SC66. This inhibitor has a dual func-
tion: it facilitates ubiquitination and degradation of AKT and inhi-
bits its activity by interfering with the binding of the AKT PH
domain to PIP3 [21]. In SkBr3 cells treated with SC66 inhibitor,
the blocking/degradation of AKT resulted in an increased phospho-
rylation/activation of PERK kinase, leading to the inactivation of
eIF2a by phosphorylation in S51, an increased expression of the
downstream target ATF4, and a concomitant upregulation of
MBP-1 (Fig. 1D). Cell viability was reduced by 60–75% (Fig. 2D).
Comparable outcomes were obtained in MCF-7 breast cancer cells
following the same treatments (Fig. 1E), and in no case
alpha-enolase expression was signiﬁcantly affected. Overall, these
results strongly support the hypothesis that ENO1 mRNA alterna-
tive translation may be controlled by the AKT/PERK/eIF2a
pathway.
Fig. 1. The treatment of breast cancer cells with ER stress inducers and PI3K-AKT signaling inhibitors results in the activation of the PERK/eIF2a pathway and increased MBP-
1 expression. (A) To set experimental conditions, SkBr3 cells were treated with the indicated concentrations of 2-DG for 24 h, alpha-enolase (Eno) and MBP-1 protein levels
were determined by immunoblotting. (B) Data were normalized to b-actin and expressed relative to the untreated control (). Each data point is the average of at least three
independent experiments, bars represent standard deviation (*P < 0.005). (C) After a 24-h treatment with 2-DG or TG at the indicated concentrations, the expression levels of
MBP-1, downstream targets ErbB2 and c-Myc, and phospho-AKT, phospho-PERK, pospho-eIF2a, ATF4 and GRP78 proteins were determined by immunoblotting. (D) SkBr3
cells were treated with the indicated concentrations of NVP-BEZ235 (BEZ), LY294002 (LY), everolimus (EVE) or SC66 for 24 h. The expression of MBP-1, phospho-AKT and ER
stress proteins was determined by immunoblotting. (E) MCF-7 cells were subjected to the indicated treatments for 24 h; as for SkBr3 cells, MBP-1 expression was upregulated
upon treatment with 2-DG, TG, BEZ, LY and SC66, but not in the presence of EVE. b-Actin is shown as a control of the total proteins loaded per lane. Results are representative
of three independent experiments with comparable outcomes.
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MBP-1 unravels the signaling pathways underlying MBP-1 expression
To conﬁrm the results obtained in SkBr3 cells and to demon-
strate an ER stress-mediated control of MBP-1 expression, we uti-
lized a HEK293T cell clone, which stably expresses recombinant
human alpha-enolase/MBP-1 proteins.
Cells were obtained by the stable transfection of an expression
vector carrying an alpha-enolase cDNA with additional epitopes: a
Flag-Tag at the NH2-terminal and a V5-Tag plus six-histidine at the
COOH-terminal. 293-T/Eno-Flag-V5 cells express both the recom-
binant multiple-epitope-tagged alpha-enolase and the
double-tagged MBP-1-V5 protein generated by the alternative
translation of the recombinant mRNA. The ectopically expressedproteins are easily distinguished by using speciﬁc anti-Tag anti-
bodies (anti-Flag and anti-V5, Fig. 3A and B), while the use of mon-
oclonal antibodies with known antigen speciﬁcity allows for the
simultaneous detection of endogenous and exogenous
alpha-enolase/MBP-1 proteins (anti-Eno 276/3 and anti-Eno 19/8,
Fig. 3C). Although wild type HEK293T cells express almost unde-
tectable levels of endogenous MBP-1, the treatment of the stably
transfected cells with 2-DG resulted in a dose-dependent increased
expression of exogenous MBP-1-V5, conﬁrming once more the ori-
gin of MBP-1 from the alternative translation of full-length
alpha-enolase mRNA (Fig. 3D).
We then subjected the cells carrying the recombinant
alpha-enolase/MBP-1 proteins to the same stimuli utilized on
SkBr3 cells and associated the expression level of ectopic
Fig. 2. Cell viability upon treatments was assessed by MTS assay. SkBr3 or 293-T/Eno-Flag-V5 (293) cells were treated with 2-DG (A), TG (B), BEZ (C) or SC66 (D) at the
indicated concentrations for 24 h. Data are expressed as the percentage of control cells and are the means ± SD of three separate experiments, each of which was analyzed in
triplicate.
Fig. 3. 293-T/Eno-Flag-V5 cells ectopically expressing recombinant alpha-enolase/MBP-1 proteins respond to 2-DG by upregulating exogenous MBP-1 protein. (A) Schematic
representation of the epitope-tagged alpha-enolase construct, the location of Flag, V5 and 6xHis tags, and of protein regions containing the epitopes recognized by anti-Eno
276/3 and anti-Eno 19/8 monoclonal antibodies are indicated. (B and C) Analysis of endogenous (End.) and exogenous (Exo.) alpha-enolase/MBP-1 proteins by
immunoblotting. Total proteins from stably transfected cells (Tr) and mock transfected cells (Cr) were separated on the same gels and probed with the indicated antibodies.
The blot in (C) was ﬁrst probed with anti-Eno 276/3 then re-probed with anti-Eno 19/8 antibody and exposed to ﬁlm for 5 times longer than the others. (D) Cells were treated
with the indicated concentrations of 2-DG for 24 h and MBP-1-V5 protein levels were determined by immunoblotting. b-Actin is shown as a control of the total proteins
loaded per lane.
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the cellular model responded to the different treatments, such as
the ones leading to an ER stress response (2-DG and TG, Fig. 4A)
and the ones interfering with the PI3K/AKT/mTOR pathway (BEZ,
LY, EVE and SC66, Fig. 4B), with an increase of MBP-1-V5 protein,
as previously observed in SkBr3 and MCF-7 cells. Cell viability data
conﬁrmed the effectiveness of the treatments (Fig. 2A–D).Brieﬂy, all treatments, except the one with EVE induced a
decrease in phospho-AKT, the upregulation of phospho-eIF2a,
and the increased expression of ATF4 and MBP-1. In conclu-
sion, the overexpression of MBP-1-V5 was consistently
driven by the inhibition of the PI3K-AKT signaling pathway
and by ER stress activation through the AKT/PERK/eIF2a
pathway.
Fig. 5. The knockdown of PERK negatively affects MBP-1 and MBP-1-V5 expression
in SkBr3 and 293-T/Eno-Flag-V5 cells, while Salubrinal treatment upregulates both
MBP-1 proteins. Cells were treated with PERK-speciﬁc double stranded siRNA (+) or
unrelated siRNA () (A, B, inner left) or with the indicated concentrations of
Salubrinal (SAL) (A, B, inner right). The expression of MBP-1, MBP-1-V5, and ER
stress proteins phospho-PERK and phospho-eIF2awas determined by immunoblot-
ting. b-Actin is shown as a control of the total proteins loaded per lane. Results are
representative of three independent experiments with comparable outcomes.
Fig. 4. The treatment of 293-T/Eno-Flag-V5 cells with ER stress-inducing drugs or
AKT inhibitors leads to an increase of the recombinant MBP-1-V5 protein. Cells
were treated with the indicated concentrations of 2-DG or TG (A) or NVP-BEZ235
(BEZ), LY294002 (LY), everolimus (EVE) or SC66 for 24 h (B). The expression of MBP-
1-V5, downstream target c-Myc, phospho-AKT and ER stress proteins was deter-
mined by immunoblotting. b-Actin is shown as a control of the total protein loaded
per lane. ER stress response and MBP-1-V5 expression were upregulated upon all
treatments except EVE. Results are representative of three independent experi-
ments with comparable outcomes.
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appears as a discrete band, while in SkBr3 cells MBP-1 protein
appears as two/three closely migrating bands of slightly different
apparent molecular weight, probably due to cell-type speciﬁc
post-translational modiﬁcations.
3.4. MBP-1 expression is downregulated by PERK knockdown and
enhanced by Salubrinal
To conﬁrm the hypothesized central role played by PERK kinase
downstream of AKT in MBP-1 expression, we silenced PERK by
siRNA transfection both in SkBr3 and 293-T/Eno-Flag-V5 cells.
The knockdown of PERK resulted in the downregulation of
phospho-eIF2a and, ultimately, in a lower expression of MBP-1
and MBP-1-V5 proteins (Fig. 5A and B).
Finally, to further rule out the involvement of ER stress response
signaling in the cap-independent translation underlying MBP-1
expression, we treated SkBr3 and 293-T/Eno-Flag-V5 cells withSalubrinal, a selective phosphatase inhibitor that prevents the
dephosphorylation of phospho-eIF2a. The treatment with
Salubrinal resulted in the upregulation of phospho-eIF2a and
increased expression of MBP-1 and MBP-1-V5 proteins, without
affecting the phosphorylation of PERK in T980. Conversely, simulta-
neous treatment with TG and Salubrinal had a synergistic effect,
increasing the levels of active phospho-PERK and inactive
phospho-eIF2a and, ultimately, of MBP-1 and MBP-1-V5 proteins
(Fig. 5A and B).
Collectively, our data indicate that the stress-induced inactiva-
tion of AKT kinase and the activation of the cellular response medi-
ated by active phospho-PERK and inactive phospho-eIF2a induces
MBP-1 expression, strongly suggesting that MBP-1 belongs to the
group of proteins selectively expressed by a cap-independentmech-
anism as a consequence of cell response to stress conditions. These
data contribute to shedding light on the signal-activation mecha-
nisms leading to MBP-1 expression and may suggest novel thera-
peutic approaches to counteract the loss of MBP-1 in breast cancers.
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